Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 19/20 | 0.68 |
| ▸ | FLT1 | P17948 | 4/20 | 0.68 |
| ▸ | AURKA | O14965 | 3/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.68 |
| ▸ | KIT | P10721 | 3/20 | 0.68 |
| ▸ | BRAF | P15056 | 4/20 | 0.53 |
| ▸ | MET | P08581 | 4/20 | 0.53 |
| ▸ | FLT4 | P35916 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289136 | 0.90 | KDR (0.71) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4280526 | 0.90 | KDR (0.63) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4282237 | 0.89 | KDR (0.67) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4289198 | 0.87 | KDR (0.62) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL3741334 | 0.86 | KDR (0.62) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4288584 | 0.86 | KDR (0.68) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4284115 | 0.86 | KDR (0.61) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4289070 | 0.86 | KDR (0.68) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4285666 | 0.86 | KDR (0.68) | KDRFLT1AURKAPDGFRBKIT | |
| SCHEMBL4282392 | 0.85 | KDR (0.67) | KDRFLT1AURKAPDGFRBKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304557-B2 | Fused heterocycle derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163488-A1 | FUSED HETEROCYCLE DERIVATIVES AND USE THEREOF | NOX3, NOX5, ZYX | KDR 2311/4885FLT1 2409/4885AURKA 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.